Copy
ESCI Newsletter - Number 34 - April 2020 


Dear ESCI Members,
dear Friends


We are living what it is likely the most serious public health concern of this generation.

The covid-19 pandemic has infected close to 1,200,000 people, killed over 60,000 people and placed billions of people in quarantine, slowing down our globalized economy, raising uncertainty in our future and raising many cracks in what we call “humanity”.

Make no mistake, this is can be a very dangerous situation if not properly managed by governments, health services and especially by the different populations. Our behaviors will determine when can we have our lives back to normal, regardless of what “normal” will be from now on.

The European Society for Clinical Investigation (ESCI), as many other biomedical Societies was deeply affected by these events. Our Annual meeting, which would have been organized in May in Bari, Italy, by Prof. Piero Portincasa, is now postponed to September 7-9. We hope that, by then, we will be out of the fog, with new lessons from this situation. It was with a heavy heart that we decided to postpone our Annual Meeting. It was a difficult decision but the local organizer and the ESCI Council decided that it would impossible to organize the meeting as expected in May. Prof. Portincasa organized a superb program, with outstanding speakers and a very attractive program. If more changes are needed, we will communicate in due time. This is a quickly flowing situation and we may need to do more changes.

While the modern society faces one of its largest challenges ever, ESCI cannot stop. Although the Central Office is mostly working from home to reduce risks, it has been working to transfer all the logistics of the Annual Meeting from May to September, while keeping on accepting new abstracts. We still have the Young Investigator and Bioart Awards calls still open, so we are still accepting applications. At the same time, ESCI is finishing the texts for the novel calls for exploratory grants as well as other types of research fellowships that will be available for young researchers and clinicians. The official announcement would have occurred in May during the opening of our Annual Meeting. We will announce the new calls in the next ASM opening. 

I would also take this chance to mention that we will go as planned elect three new Councilors for the Council. You will read more about the three candidates in this newsletter. Ballots have been sent to ESCI members.

Finally, a word of endless appreciation to all health professionals that are in the frontline of this war against a microscopic, but very dangerous, enemy, greatly risking their own health (and lives) to help others. As for the rest of us (basic scientists, for example) who are not in the frontline, we can help through contributing for a proper population behavior during a pandemic of this nature, and for spreading assertive and correct information, debunking myths and pseudo-science that do more harm than good. Ignorance and panic are as dangerous as any pandemic.  

Be well and safe and see you in Bari for the next ASM. Keep following our newsletters and website for more information. Also follow the latest papers published at the European Journal of Clinical Investigation (and please, also submit your best work there).

Thank you for your attention. Together, we will beat this
 

Best regards 


Paulo J. Oliveira, Ph.D. 
ESCI President


Dear colleagues and friends,


The new editorial board of the European Journal of Clinical Investigation (EJCI) started in January 2020. Our perspectives  how to manage a scientific journal has been published in the first  issue of  EJCI  this year (A PDF is included).
The first three months was very extensive but also very exciting. Fortunately we are getting more and more grip on the management of this important journal.  The editorial board consist of 28 members ( editor/ deputy editor in chief, 2 managing editors, 4 deputy editors and 20 section editors).  We have a great editorial team that needs your help for further improvement of the journal. First, we need good and dedicated reviewers in almost all areas of research. Second, we need section editors in the following research areas: pulmonology, neurology, critical care and epidemiology. Third, we are inviting you and your colleagues to submit your scientific work to our journal. A great example is the recent editorial  from our previous editor in chief, prof. John Ioannidis, regarding the corona pandemic (A PDF is included). We warmly invite you to join our team and asking you to contact us by sending an e-mail to the editorial office (ejcioffice@esci.eu.com). You are also invited to visit the website of our  journal: https://onlinelibrary.wiley.com/journal/13652362

On behave of the editorial board, 

Hendrik Nathoe, editor in chief.

New members of the ESCI Council

Marcin Krawczyk 

(born 10.07.1982) studied medicine at the Medical University of Lublin (Poland). In 2009 he moved to Homburg (Saarland, Germany) where started working as a physician in the Department of Medicine II (Gastroenterology & Endocrinology) at Saarland University Medical Centre. In addition to providing healthcare to his patients, he performed research concerning non-invasive markers of liver diseases with a special focus on genetic modifiers of disease progression. In 2015 he joined the Medical University in Warsaw where he was appointed as the Head of the newly opened Laboratory of Metabolic Liver Diseases. He is an author / co-author of > 100 scientific papers (cumulative IF 466). ESCI member since 2007 regularly presenting results of his studies at the ASM ESCI meetings as posters and oral presentations. 

Dr. Gemma Vilahur,
DVM, PhD, FESC


Dr. Gemma Vilahur is a Senior Researcher and Group Leader at the ICCC-Research Institute of the Hospital de la Santa Creu i Sant Pau (Barcelona) since her return from the United States (New York, Mount Sinai School of Medicine) in 2006.
Her research activities focus on ischemic heart disease, from athero-thrombosis to cardioprotection, and the impact of co-morbidities on cardiovascular disease. She has published 132 articles (3.700 citations, H-index=35) including original manuscripts, consensus and position papers, and reviews.  In addition, she has contributed to 31 book chapters. She is and has been principal investigator and co-investigator of multiple research projects (National and European projects either funded by public agencies or industry) and is a Management Committee member of an EU-COST action. Dr. Vilahur’s research has been awarded by multiple National and International Scientific Societies. In this regard, it deserves to mention that she has received the L’Oreal-UNESCO foundation - for Women in Science (2012) and the Outstanding Achievement Award from the European Society of Cardiology (2019). She is co-author of 4 patents, co-founder of 2 Spin-Off, and holds positions of trust in different National and International Scientific Societies. 

Within ESCI, I will devote my expertise, background and energy towards increasing the interest in basic, translational and clinical research amongst the European physician/scientists with the aim to improve cardiovascular health. I will also put my efforts into further expanding the scientific, educational and advocacy activities of the Society as well as improving the communication and networking opportunities, particularly among the youngest. 
 



Nahid Nathalie Tabibadeh

My journey through translational research and medicine started early during my medical studies. While I was a medical student, I earned a Bachelor degree in Immunology in 2004, and in Genetics in 2005 in Paris.

During my residency program in Internal Medicine and in Nephrology, I earned a Masters Degree in Immunology in 2013. During my fellowship in Renal Physiology, I had the opportunity to follow an M.D., Ph.D. program and earned my PhD degree in 2014 in Physiology. This dual training led me to always keep a “bench to bedside” and a “bedside to bench” point of view. During my fellowship, I specialized in renal physiology, and pathophysiology, especially metabolic consequences of chronic kidney disease, and urolithiasis. In particular, I focus on physiology of renal concentrating mechanisms, during health and disease, such as chronic kidney disease, urolithiasis, or renal toxicity of various drugs. Today I continue to do research on these fields in APHP Hôpital Bichat and in the University of Paris, and currently heading one clinal trial, two observational studies and two translational studies.

Benefits of being an ESCI member:

•      Unique community of fundamental and clinical researchers

•      Free subscription to the European Journal of Clinical Investigation (EJCI)

•      15% discount on books by Wiley

•      Discount on the ESCI Annual Scientific Meeting registration

•      Access to future exclusive contents

•      Pay a low individual subscription (€ 25/year). 


The European Society for Clinical Investigation sponsors the following awards:
 

•    Best Clinical Research Article published at the EJCI

•    Best Basic Research Article published at the EJCI

•    Young Investigator Award

•    Bio Art Award

•    Poster Awards

•    Travel Awards to attend the Annual Meeting

You can apply for ESCI membership by using the application form on our website: www.esci.eu.com

Please consider becoming a member of the European Society of Clinical
Investigation. Next Anual Meetings in Bari, Italy (2020), Prague,
Czech Republic (2021) and Warsaw, Poland (2022).
Facebook
Twitter
Website
Email
Copyright © 2020 European Society for Clinical Investigation, All rights reserved.


Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp


Questions or remarks? Mail us at: esci@umcutrecht.nl